Objective: To investigate the impact of obesity, weight loss and oral glucose ingestion on serum visfatin and vaspin levels in prepubertal children. Subjects and methods: A total of 100 prepubertal obese Caucasian children (OB) and 42 controls (C) were studied. The OB group was studied at baseline and after moderate (n ¼ 46) and extensive (n ¼ 14) body mass index (BMI) reduction by conservative treatment, undergoing body composition studies (dual-energy X-ray absorptiometry) and oral glucose tolerance tests (OGTTs). Serum visfatin and vaspin levels were studied throughout the OGTT, as were their relationships with insulin, leptin, leptin soluble receptor (sOB-R), adiponectin (total and high molecular weight), resistin, interleukin-6 (IL-6) and tumor necrosis factor-a levels at every time point. Results: OB had higher visfatin (Po0.001), but similar vaspin than C. BMI reduction decreased visfatin levels (Po0.001), with BMI, waist circumference and the surrogate markers of body fat (leptin and sOB-R) showing significant correlations (Po0.05) with this peptide, but not with vaspin. Visfatin and vaspin decreased during the OGTT (Po0.001). Weight reduction did not alter visfatin dynamics in the OGTT, but decreased the area under the curve (AUC) for vaspin (Po0.001), with a correlation between the AUCs for vaspin and insulin after weight loss (Po0.05). Visfatin levels were positively correlated with resistin and IL-6, after controlling for BMI and HOMA (homeostatic model assessment) index at every time point in the study. Conclusion: Serum visfatin, but not vaspin, levels are influenced by body fat content in obese children, whereas both adipokines are modulated by glucose intake in a BMI-dependent manner.
Introduction
The rising prevalence of obesity and its associated comorbidities observed in the past three decades, especially in young children, has resulted in increased research focused on its causes and consequences. One of the main outcomes of this investigation has been the full acceptance of the adipose tissue as a true endocrine organ, 1 having a pivotal role in energy homeostasis and especially in carbohydrate metabolism regulation. Adipose tissue exerts its influence on glucose metabolism in a dual fashion, first as a target organ storing the excess carbohydrate and lipid intake, thus avoiding its ectopic deposition, and second through the secretion of various adipokines that influence insulin sensitivity. 1 Among these, proinflammatory molecules such as interleukin-6 (IL-6), tumor necrosis factor-a and resistin have been shown to induce insulin resistance. 2 In contrast, adiponectin, especially its high-molecular-weight isoform, 3 was the only adipokine initially discovered to be insulin sensitizing.
Recently, two adipokines, pre-B-cell colony-enhancing factor/NAMPT (nicotinamide phosphoribosiltransferase)/ visfatin 4, 5 and the visceral adipose-tissue-derived serine protease inhibitor/vaspin, 6 with potential insulin secretagogue or sensitizing properties, have been described. Visfatin was shown to induce hypoglycemia in mice and to phosphorylate the insulin receptor and its related substrates 1 and 2 in vitro, 7 although these insulin-like actions have not been fully confirmed. In humans, this cytokine is produced mainly by adipose tissue, but also by leukocytes, hepatocytes and muscle cells. 5 A positive correlation between serum visfatin levels and body fat content and a decrease after weight reduction have been described, 8 and in spite of its name, there is no evidence that its expression is higher in visceral than in subcutaneous adipose tissue. 9 Serum visfatin levels are relatively low, and although it is currently thought that this peptide is important for normal insulin secretion, the correlation between visfatin levels and type 2 diabetes and other states of insulin resistance is variable. 5 Vaspin belongs to the serpin (serine protease inhibitor) family and its precise inhibitory activity is unknown. Its expression has been demonstrated in human visceral and subcutaneous adipose tissue, with a suggested depot-specific regulation either by body fat content or by insulin sensitivity. 10 The circadian rhythm of the serum levels of human vaspin has been recently described. 11 However, there are contrasting reports regarding the relationship between vaspin levels, body mass index (BMI) and carbohydrate metabolism impairment, 12, 13 as well as regarding the influence exerted by physical training and weight reduction on its circulating levels. 14, 15 To date, the studies analyzing visfatin [16] [17] [18] and vaspin levels 19, 20 in children and adolescents are sparse and, to our knowledge, nonexistent in young prepubertal children. Moreover, the lack of pharmacological treatments for obesity in this age range poses great difficulties in the achievement of large weight reduction based exclusively upon conservative treatment. Thus, the analysis of eventual diagnostic markers or therapeutical targets in this age range is of great interest. The aims of this study were: (1) to investigate the influence of obesity on serum visfatin and vaspin levels in prepubertal children; (2) to prospectively evaluate the effect of different degrees of weight loss on the circulating levels of these adipokines; and (3) to analyze the effect of oral glucose ingestion on the circulating levels of these peptides, both before and after weight reduction, as well as their relationship with glucose and insulin throughout an oral glucose tolerance test (OGTT). SDS (range À1.5 to 1.5), respectively. All patients and controls and their parents or guardians gave informed consent as required by the local ethics committee, which had previously approved the study. Control children were referred to our department, but were found to be normal with no pathological auxological, clinical or analytical findings, and were drawn in a single fasting sample. Obese patients were studied to rule out any underlying pathological condition before their enrollment in the study. Their management was based on three main aspects: (1) behavioral treatment focused on stress/anxiety control techniques and conduct modification strategies on the basis of classical conditioning; (2) age-oriented selfregistered physical activity; and (3) reorganization of eating habits, with a self-registered eating schedule and the prescription of a hypocaloric mix diet, with a 10% restriction on the estimated basal metabolic rate according to the Schoffield equation. The obese cohort was analyzed at baseline (B, n ¼ 100), after reducing their BMI by 1 SDS (À1, n ¼ 46) and again in those patients achieving a second SDS BMI reduction (À2, n ¼ 14; Figure 1 ).
Subjects and methods

Subjects
BMI and waist circumference were recorded. Lumbar spine bone mineral density (L1-L4) and body composition analyses by dual-energy X-ray absorptiometry analysis (QDR4500W; Hologic, Bedford, MA, USA) and OGTT (1.75 g of glucose per kg; maximum 75 g) were performed at time points B and À2 in obese patients. Data were standardized according to appropriate ethnic-, gender-and age-matched control references. 21, 22 The means of three digital measurements of systolic and diastolic blood pressure were registered at every time point (Critikon, Dinamap Vital-Sign-Monitor: 8100, Tampa, FL, USA). Blood samples were obtained at every time point of the OGTT tests and throughout follow-up from patients and at a single visit from controls after overnight fasting. They were then centrifuged and serum stored at À80 1C until assayed.
Biochemical measurements
Serum visfatin and vaspin levels were determined by enzyme immune analysis (Adipogen, Incheon, Korea), with sensitivity limits of 0.03 ng ml -1 and 12 pg ml -1 , respectively, and intra-and inter-assay variation coefficients ranging between 3.46 and 5.53% and between 6.31 and 9.53% for visfatin and below 5 and 10% for vaspin, respectively. 23 Glucose, insulin, leptin, leptin soluble receptor (sOB-R), total and highmolecular-weight adiponectin, resistin, IL-6 and tumor necrosis factor-a were measured using commercial assays as ). The total area under the curve (AUC) for glucose, insulin, visfatin and vaspin levels throughout the OGTT was calculated using the following formula:
. 25 
Statistical analysis
All data are reported as the mean±s.d. Log transformation was performed on visfatin data, as they did not fit a Gaussian distribution in order to use parametric tests. Nonparametric tests were used for analysis of vaspin data, as they did not fit a normal distribution even after log transformation. Student's t-test was used for comparison of visfatin levels between independent groups, whereas Mann-Whitney U-test was used for vaspin. Changes in single normal parameters for each patient were studied using either Student's t-test for paired samples or analysis of variance for repeated measurements preceded by Mauchly's W-test and followed by Scheffé's test with Bonferroni's adjustment for visfatin. Wilcoxon and Friedman tests were used for vaspin. The relationships between quantitative normal variables were studied by linear correlation analysis (Pearson's r), whereas Spearman's rho was used for nonnormally distributed variables. A value of Po0.05 was chosen as the level of significance. Statistical analyses were performed using SPSS 11.0 software for Windows (MapInfo Corporation, Troy, NY, USA).
Results
Study at baseline (B)
As previously reported for metabolic parameters and other adipokines in healthy and obese prepubertal children, 24 no differences between sexes were found in visfatin (girls 1.47 ± 1.26; boys 1.62 ± 1.36 ng ml -1
; P ¼ 0.527) or vaspin levels (girls 0.40±0.39; boys 0.33±0.32 ng ml -1 ; P ¼ 0.243); consequently, metabolic and hormonal data from males and females were pooled for later analyses.
The demographic and anthropometrical characteristics and the metabolic and adipokine profiles of the studied populations at baseline are shown in Table 1 ; Po0.001), but vaspin levels were not different between the groups (OB: 0.34 ± 0.34 vs C: 0.34 ± 0.33 ng ml -1 ; P ¼ 0.964; Figure 2 ). In the entire studied population, visfatin levels were positively correlated with both absolute (kg m -2 ) and relative (SDS) BMI (r ¼ 0.41 and r ¼ 0.36, respectively, Po0.001), as well as with waist circumference (r ¼ 0.22, Po0.05), insulin (r ¼ 0.25, Po0.01) and HOMA index (r ¼ 0.31, Po0.01), although these last three correlations lost their significance after controlling for BMI. Significant correlations of visfatin were also found with resistin, IL-6, leptin, sOB-R, total and LDL cholesterol and with the atherogenic index. After controlling for the effect of BMI and HOMA index, Visfatin and vaspin in young obese children GÁ Martos-Moreno et al significant partial correlations of visfatin remained exclusively with resistin (r ¼ 0.36, Po0.001) and IL-6 (r ¼ 0.28, Po0.05). No significant correlation between vaspin levels and any of the studied variables was found.
Changes after weight reduction in obese patients
Comparison between dual-energy X-ray absorptiometry analysis scans in obese patients at time points B and À2 (n ¼ 14) showed no changes in lean mass ( The reduction of BMI in 1 SDS decreased visfatin levels (n ¼ 46, 2.01 ± 1.61 ng ml -1 at B vs 1.27 ± 1.05 ng ml -1 at À1, Po0.001). In those patients with progressive À1 and À2 SDS BMI reduction (n ¼ 14), this initial decrease in visfatin levels from B to À1 was also present, but no further decrease was observed when they achieved the À2 SDS BMI reduction. In contrast, vaspin levels did not change significantly after weight loss (P ¼ 0.286), although a nonsignificant decrease was observed after 1 SDS BMI reduction (n ¼ 46; 0.35 ± 0.37 at B vs 0.28±0.38 at À1; P ¼ 0.125; Figure 3 ).
Effect of oral glucose ingestion in obese patients
In obese patients at baseline, visfatin levels decreased significantly and progressively throughout the OGTT (n ¼ 77; Po0.001, Figure 4a ). In contrast, a decrease in Visfatin and vaspin in young obese children GÁ Martos-Moreno et al vaspin levels was observed 120 min after glucose ingestion (Po0.001, Figure 4b ). When the OGTT was repeated in those patients who achieved À2 SDS BMI reduction (n ¼ 14), the decrease in visfatin after glucose ingestion was more precocious and abrupt (Po0.001, Figure 4c ), whereas now no significant changes were observed in vaspin levels during the OGTT (P ¼ 0.978; Figure 4d ). At baseline, the AUC for visfatin and vaspin did not correlate with each other or with the AUC for glucose or insulin. In contrast, as expected, a positive correlation was found between the AUCs for glucose and insulin (r ¼ 0.64; Po0.001).
When comparing the AUCs between B and À2 time points in those patients achieving a À2 SDS BMI reduction, no changes in glucose or visfatin AUCs were observed as a consequence of weight loss. On the contrary, both AUCs for insulin (1042±618 at B vs 627 ± 375 pmol l -1 at À2; Po0.001) and vaspin (0.66 ± 0.48 at B vs 0.38 ± 0.42 ng ml -1 at À2; Po0.01) decreased in those patients reducing their BMI by 2 SDS; with a novel correlation between the AUCs of vaspin and insulin (r ¼ 0.59; Po0.05) arising at time point À2.
Discussion
In this study we have demonstrated that obese prepubertal children have higher visfatin, but similar vaspin levels compared with lean controls, and how BMI reduction significantly decreases serum visfatin levels. Moreover, we show that in obese children both visfatin and vaspin levels decrease as a consequence of glucose ingestion, and how the glucose-induced drop in vaspin levels was abolished after weight loss. Finally, a relationship was shown between visfatin levels and the proinflammatory adipokines resistin and IL-6, independently of their BMI or HOMA index.
To evaluate the relationship between visfatin levels and body fat content, a three-way approach was performed:
(1) The comparison between lean and obese children; (2) The study of visfatin's relationship with other adipokines; (3) The evaluation of the effect of weight loss on visfatin levels.
Relationship between visfatin levels and BMI status Higher circulating visfatin levels in obese children and their positive correlation with BMI have been previously reported; [16] [17] [18] however, these series pooled children and adolescents together, thus masking the possible effect of pubertal developmental stage and sex steroid influence. Hence, the demonstration of increased visfatin levels in a cohort made up exclusively of young prepubertal obese children constitutes an original contribution of this study. Although visfatin is abundantly expressed in adipose tissue, which is its main source, 9 it is unclear whether it represents a marker of adipose mass or function. The positive correlation between visfatin levels and BMI suggest that it may indeed be a marker of adipose mass. In contrast, the disappearance of the correlation between visfatin levels and waist circumference after controlling for BMI suggests that visfatin levels in obese children are influenced primarily by the total amount of body fat and not by its distribution. This is consistent with previous observation showing similar visfatin expression in visceral and subcutaneous adipose depots.
9
Relationship between visfatin levels and other adipokines Higher leptin and lower sOB-R levels constitute surrogate markers of increased body fat in prepubertal children; 24 thus, the similar dynamics of leptin and visfatin observed here, the correlations of visfatin levels with those of leptin (positive) and sOB-R (negative) and its disappearance after controlling for BMI suggest that the increase in body fat in obese children underlies the observed increase in visfatin levels. The lack of correlation between visfatin and either total or high-molecular-weight adiponectin levels could be because of the young age of the patients studied. This could allow for their adipose tissue to recruit preadipocytes in a higher rate than observed in adults, thus limiting adipocyte hypertrophy and adiponectin secretion impairment, as previously postulated. 24 This particularity in the secretion of adiponectin by adipose tissue in children could be biasing the eventual correlation of its circulating levels with those of visfatin.
Relationship between visfatin levels and changes in BMI One of the main outcomes of this prospective study is the effectiveness of the scheduled program for weight loss in this young cohort, with almost half the cohort achieving substantial weight loss (À1 SDS) and 14% of the enrolled patients extending it further (À2 SDS). This has allowed us to 
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prospectively analyze the effect of fat mass reduction on the studied adipokines, as well as on their pathophysiological relevance. The effect of weight loss on serum visfatin levels is still unclear, as both a decrease 26 and an increase 27 in circulating visfatin after extensive weight loss in obese adults following surgical procedures have been reported. In this study we report the effect of different degrees of weight loss on visfatin levels in young prepubertal children, with visfatin decreasing with a loss of 1 SDS of the initial body weight. This decrease was sustained with more extensive weight loss, but did not decrease further.
To evaluate the pathophysiological implications of visfatin, we studied its relationships with:
(1) Parameters of carbohydrate metabolism, after fasting and after an OGTT; (2) Parameters of lipid metabolism; (3) Inflammatory markers.
Relationship between visfatin levels and parameters of carbohydrate metabolism The described evolution of visfatin levels after weight loss, which is parallel to that of insulin and HOMA, could also indicate that the decline in visfatin levels is not exclusively driven by the decrease of body fat, but more importantly influenced by the improvement in insulin resistance, resulting in a decrease in endogenous insulin. These changes resemble the decrease in visfatin levels reported after a somatostatin-induced decrease in endogenous insulin secretion, 28 and suggest that the improvement of insulin sensitivity secondary to weight loss and the increase in cellular glucose caption could downregulate visfatin secretion. Similarly, the increase in glucose uptake following the OGTT could be responsible for the drop in visfatin levels observed, with this mechanism enhanced by the insulin sensitization derived from weight loss, which would fit the abrupt decrease in visfatin observed in the OGTTs performed at À2. This is consistent with the previous observation that after an OGTT, visfatin levels and AUCs are lower in lean compared with obese women. 29 The fact that the correlations between visfatin and insulin and HOMA in our young obese patients disappeared after controlling for the effect of BMI suggest that the relationship between visfatin and carbohydrate metabolism could be, at least partially, mediated by body fat content or, more probably, that visfatin levels are under the dual influence of body fat and carbohydrate metabolism status. However, taken together, these data suggest another possibility. As our young patients did not display any gross alteration in carbohydrate metabolism, the high basal visfatin levels could be the result of a compensatory mechanism to maintain long-term glucose homeostasis, which returns to normal after weight loss. In contrast, rapid increases in glucose and insulin in the short term (OGTT) are able to decrease this proinsulin-sensitizing profile.
Relationship between visfatin levels and lipid metabolism A direct relationship between circulating visfatin levels and tissue mRNA levels and cholesterol levels has been demonstrated in lean and obese adults. 30 Given their influence on visfatin levels, it has been suggested that this finding could be an epiphenomenon driven by changes in BMI and/or carbohydrate metabolism. The fact that the correlation of visfatin with total and LDL cholesterol lost its significance after controlling for both parameters in our cohort supports this hypothesis.
Relationship between visfatin levels and inflammation Finally, the correlation observed between visfatin and both resistin and IL-6 levels, even after controlling for the eventual bias that BMI or insulin resistance could exert, could be determined by the fact that, in a similar fashion as these proinflammatory molecules, 31 Thus, this adipokine could be contributing to the generation of the low-grade inflammation state associated with obesity and may be useful as a marker of this condition. However, when contrasting all of our observations with previously published results, it must be taken into account that significant differences in the qualitative and quantitative detection of visfatin by immunoassays have been reported in a previous comparative study. 23 This might explain some of the conflicting observations reported with respect to the eventual correlation of circulating visfatin with obesity or insulin resistance.
Relationship between vaspin levels and anthropometric and metabolic parameters. Vaspin levels did not differ between controls and obese prepubertal children, nor did they change after weight loss. Furthermore, we found no significant correlation between vaspin, BMI, HOMA or insulin levels. Two recent studies report higher vaspin levels in obese children 19 and a decrease after a short-term lifestyle modification program. 20 However, these studies have conflicting results regarding the correlation of vaspin levels with insulin or HOMA index, with both negative 20 and positive 19 correlations being reported. Moreover, it was recently observed that these variables are unrelated to vaspin levels in nondiabetic humans, 12 whereas changes are observed in those patients showing a more severe impairment of carbohydrate metabolism. 14 This suggests that, as previously stated for visfatin, the regulation of vaspin synthesis is most likely driven not only by changes in BMI, but also by carbohydrate metabolism. This is consistent with previous reports 13, 14 showing changes in vaspin levels as a consequence
Visfatin and vaspin in young obese children GÁ Martos-Moreno et al of increased insulin resistance or type 2 diabetes mellitus. Again, the lack of gross alterations in carbohydrate metabolism in our young cohort could underlie the sparse relationship observed between vaspin and BMI or HOMA. However, some authors do not report an association between vaspin levels and carbohydrate metabolism impairment 15 and postulate physical training as a possible regulator of vaspin levels, 15, 36 with some authors suggesting that the regulation of vaspin synthesis could be depot specific. 10 Our finding that glucose ingestion at baseline causes a decrease in vaspin levels is similar to studies in animals 37 and, recently in humans, that show a postprandial decrease in serum vaspin levels after every meal. 11 The lack of glucose ingestion-induced drop in vaspin levels next to the correlations between vaspin and insulin AUCs observed in the OGTTs performed after weight loss (À2) support the hypothesis of a complex regulation of vaspin levels involving body fat content and insulin sensitivity status as main modulators of vaspin secretion, with acute rise in glucose and insulin potentially exerting a suppressive effect on vaspin secretion. In summary, in young prepubertal children, the regulation of the levels of the adipokines, visfatin and vaspin are influenced by complex mechanisms involving body fat content and, more importantly, insulin sensitivity status and cellular glucose caption. Visfatin seems to be involved in the generation of the low-grade proinflammatory environment observed in obesity already at early ages and its secretion is more influenced by the changes in body fat than that of vaspin. Thus, on the basis that the initial metabolic impairment in childhood obesity can be subtle and difficult to detect, the determination of these two adipokines could be useful to better address the insulin sensitivity status of prepubertal obese children, complementing the information afforded by usual tests. Moreover, serum visfatin levels could also constitute a useful parameter to monitor the effect of weight changes following therapy in young obese children.
